BMS immunocombination therapy Opdivo+Yervoy is approved by NICE for the treatment of patients with advanced bowel cancer

Compilenewborn

The National Institute of Health and Clinical Excellence (NICE) recently released a final assessment document (FAD) recommending the use of Bristol-Myers Squibb's immunocombination therapy Opdivo+Yervoy for the treatment of certain patients with advanced bowel cancer, specifically: receiving fluoropyrimidine Patients with advanced bowel cancer who have failed chemotherapy and have rare microsatellite instability (MSI-H) or mismatch repair defect (dMMR) mutations

BMS said in a statement that this approval makes Opdivo+Yervey the first immune combination therapy approved for these patients in the UK

The approval is based on data from the ongoing Phase 2 CheckMate-142 study

Colorectal cancer (CRC) is a type of cancer that occurs in the colon or rectum

Opdivo+Yervoy is the only dual immunotherapy program that has received regulatory approval

Last month, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) also issued a positive review of the Opdivo+Yervoy regimen, recommending approval of the regimen for the treatment of disease progression after previous fluoropyrimidine-based combination chemotherapy , DMMR or MSI-H metastatic CRC adult patients

Opdivo+Yervoy is a unique immune combination that targets 2 different immune checkpoints (PD-1 and CTLA-4).

According to the information on the Bristol-Myers Squibb website, up to now, the Opdivo+Yervoy program has been approved for 6 cancers and 7 therapeutic indications, which vary from country to country, including: melanoma, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma Cancer, non-small cell lung cancer, malignant pleural mesothelioma

Reference source: Opdivo plus Yervoy scores NICE backing for certain bowel cancer patients